198 related articles for article (PubMed ID: 30277012)
1. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
2. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
3. BRN2 and MITF together impact AXL expression in melanoma.
Simmons JL; Neuendorf HM; Boyle GM
Exp Dermatol; 2022 Jan; 31(1):89-93. PubMed ID: 33119145
[TBL] [Abstract][Full Text] [Related]
4. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
8. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
9. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
[TBL] [Abstract][Full Text] [Related]
10. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
11. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
12. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
14. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
[TBL] [Abstract][Full Text] [Related]
15. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
[TBL] [Abstract][Full Text] [Related]
16. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
Vachtenheim J; Ondrušová L
Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
[TBL] [Abstract][Full Text] [Related]
17. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
Goodall J; Carreira S; Denat L; Kobi D; Davidson I; Nuciforo P; Sturm RA; Larue L; Goding CR
Cancer Res; 2008 Oct; 68(19):7788-94. PubMed ID: 18829533
[TBL] [Abstract][Full Text] [Related]
18. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
[TBL] [Abstract][Full Text] [Related]
19. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
Gopal YN; Rizos H; Chen G; Deng W; Frederick DT; Cooper ZA; Scolyer RA; Pupo G; Komurov K; Sehgal V; Zhang J; Patel L; Pereira CG; Broom BM; Mills GB; Ram P; Smith PD; Wargo JA; Long GV; Davies MA
Cancer Res; 2014 Dec; 74(23):7037-47. PubMed ID: 25297634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]